As of Nov 27
| 0.00 / 0.00%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 8.00, with a high estimate of 15.00 and a low estimate of 6.00. The median estimate represents a +115.05% increase from the last price of 3.72.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.